이십대이십 바이오랩스(AIDX) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

AIDX

20/20 Biolabs Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$0.45

-0.04 ▼ -8.31%

🌙 7월 28일 7:31 AM ET (한국 7/28 20:31)

$0.43

-0.02 ▼ -4.36%

이십대이십 바이오랩스(AIDX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$6M

스몰캡

P/E

배당수익률

없음

52주 위치

저점 -8% · 고점 -99%

애널리스트

적극 매수

Fundamental health

vs. 성장주 초소형주· based on 2 axes

수익성

데이터 부족

성장

Top 58%

밸류에이션

데이터 부족

재무 안정

Top 48%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-	Insider Own ⓘ	33.61%	Shs Outstand ⓘ	10.4M	Perf Week ⓘ	-12.07%
Market Cap ⓘ	0.01B	Forward P/E ⓘ	-	EPS next Y ⓘ	9.52%	Insider Trans ⓘ	-	Shs Float ⓘ	8.1M	Perf Month ⓘ	-23.73%
Enterprise Value ⓘ	0.00B	PEG ⓘ	-	EPS next Q ⓘ	-0.12	Inst Own ⓘ	2.46%	Short Float ⓘ	3.06%	Perf Quarter ⓘ	-72.55%
Income ⓘ	-	P/S ⓘ	-	EPS this Y ⓘ	44.74%	Inst Trans ⓘ	36.51%	Short Ratio ⓘ	0.31	Perf Half Y ⓘ	-
Sales ⓘ	-	P/B ⓘ	1.84	EPS next 5Y ⓘ	17.29%	ROA ⓘ	-	Short Interest ⓘ	0.25M	Perf YTD ⓘ	-99.1%
Book/sh ⓘ	0.24	P/C ⓘ	1.31	EPS past 3/5Y ⓘ	- 3.6%	ROE ⓘ	-	52W High ⓘ	-99.1% ($50.00)	Perf Year ⓘ	-
Cash/sh ⓘ	0.34	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-43.03% -2.58%	ROIC ⓘ	-	52W Low ⓘ	-8.31% ($0.49)	Perf 3Y ⓘ	-
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	4.55%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	7.14% 9%	Perf 5Y ⓘ	-
Dividend TTM ⓘ	-	EV/Sales ⓘ	-	Sales Y/Y TTM ⓘ	-	Oper. Margin ⓘ	-	ATR (14) ⓘ	0.07	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	1.78	EPS Q/Q ⓘ	47.92%	Profit Margin ⓘ	-	RSI (14) ⓘ	27.81	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.82	Sales Q/Q ⓘ	-2.11%	SMA20 ⓘ	-18.96% ($0.56)	Beta ⓘ	-	Target Price ⓘ	$5
Payout ⓘ	-	Debt/Eq ⓘ	0.34	Earnings ⓘ	2026/5/20	SMA50 ⓘ	-40.86% ($0.76)	Rel Volume ⓘ	0.12	Prev Close ⓘ	$0.49
Employees ⓘ	14	LT Debt/Eq ⓘ	0.16	EPS/Sales Surpr. ⓘ	-180% -54.63%	SMA200 ⓘ	-76.65% ($1.93)	Avg Volume(3M) ⓘ	0.81M	Price ⓘ	$0.45
IPO ⓘ	2026/2/19	Option/Short ⓘ	No/Yes			Trades ⓘ	346	Volume ⓘ	100,468	Change ⓘ	-8.31%

📊 20/20 Biolabs Inc (AIDX) Investment Analysis

What kind of company is 20/20 Biolabs Inc?

이십대이십 바이오랩스(AIDX) 성장주

Healthcare · Medical Devices

Small-Cap — Low Volume, High Volatility

🩸 20/20 BioLabs () is a US medical diagnostics company that uses AI-powered blood tests to detect cancer and chronic diseases at an early stage. Its flagship product, OneTest™, is a Multi-Cancer Early Detection (MCED) test that screens for multiple cancers from a single blood draw. It is used in public health initiatives such as firefighter cancer screening programs and is a micro-cap healthcare stock newly listed on Nasdaq in early 2026.

Learn more about 20/20 Biolabs Inc →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5638

Employees14people

IPO2026/02/19

Current Price$0.45 ≈ 617원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 20일 (수) · 장 마감 후 EPS -180.0% 매출 -54.6%

🔔 Earnings release 2026년 2월 25일 (수) · 장 마감 후

Is it profitable?

Financial health solid

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.34

✓ Healthy debt

My positionMid-range

Low range Average High range

Medical Devices Median 0.39

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

1.82

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 2.91

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

1.78

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 2.09

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$5.00

현재가 대비 +1011.1%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+9.5%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+17.3%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-180.0%

평균 서프라이즈

2026.05.20

하회

실적 $-0.28 · 예상 $-0.10 -180.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+44.7%

양호

My positionMid-range

Low range Average High range

성장주 초소형주 Median 21.2% · Top 25%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+9.5%

평균

My positionMid-range

Low range Average High range

성장주 초소형주 Median 13.9% · Bottom 40%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+17.3%

평균

My positionMid-range

Low range Average High range

성장주 초소형주 Median 21.6% · Bottom 29%

📊 How much has it grown? (actual results)

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+3.6%

평균

My positionMid-range

Low range Average High range

성장주 초소형주 Median 12.0% · Bottom 34%

Past 5-Year Revenue

How much revenue grew over the past 5 years

-2.6%

평균

My positionMid-range

Low range Average High range

성장주 초소형주 Median 7.5% · Bottom 25%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-2.1%

평균

My positionMid-range

Low range Average High range

성장주 초소형주 Median -2.1% · Around average

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Returns by period

Current position within 52-week range

Low (-8.3%p) High (-99.1%p)

Current price is 8.3% above the 52-week low and 99.1% below the 52-week high

Recent risk (last 109 trading days)

Max drawdown

-98.1%

Annualized volatility

169.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 109-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

Current price $0.45 fell below the lower band ($0.47). Selling pressure excessive; worth watching for a short-term bounce. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD -0.081 · Signal -0.092 · Hist 0.011. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

RSI 27.7 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 0.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

In line with peers on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Mid-range

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

1.84x

✓ Fair

My positionMid-range

Low range Average High range

Medical Devices 초소형주 median 1.15x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

Analyst target price (reference)

$5.00 vs. current price +1011.1%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Medical Devices 초소형주

Who owns it?

Ownership flow is positive

Institutional net buying +36.5% · Short interest light 3.1% · Short interest fell -3.0%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+36.5%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 2.5%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 33.6%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 63.9%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

3.1%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days 📉 -3.0%p decrease

Short interest days to cover

0.3 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 10.4M주

Float (tradable shares) 8.1M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
AIDX This Stock	$5.5M	-	1.8 ▲	-	-	-8.3%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 이십대이십 바이오랩스(AIDX)?

이십대이십 바이오랩스(AIDX) belongs to the Healthcare sector and operates in the Medical Devices industry.

What is the market cap of AIDX?

The market cap of AIDX is approximately $6M, ranking 5,638 within its sector.

What is the 52-week high and low for AIDX?

AIDX has recorded a 52-week high of $50.00 and a low of $0.49.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.